Author

Vadim Levitt

Ariel University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Anjana Edathil Kadangodan· 2 shared Julia A. YaglomiD· 2 shared Michael Y. ShermaniD· 2 shared Valid GahramanoviD· 2 shared Albert PinhasoviD· 1 shared Andriy MarusykiD· 1 shared Arkadi HesiniD· 1 shared Bar Levi· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Anjana Edathil Kadangodan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Systematic Generation of Mutations at Topoisomerase II Cleavage Sites Enables Cancer Adaptation to Doxorubicin Therapy

Valid Gahramanov, Anjana Edathil Kadangodan, Riham Barazi, Arkadi Hesin, Julia A. Yaglom, Vadim Levitt, Yaakov Maman, Michael Y. Sherman

The paper shows that cancer cells develop resistance to doxorubicin by accumulating mutations at Top2 cleavage sites, which prevent DNA damage and promote adaptation.

bioRxiv · Aug 21, 2026 · PreprintCancer Biology

Mega-frequency mutagenesis: generation of non-random precise mutations with extremely high frequency upon adaptation of cancer cells to drugs and stress

Victor Oleynik, Anjana Edathil Kadangodan, Valid Gahramanov, Subha Ranjan Das, Bar Levi, Julia A. Yaglom, К. И. Аношкин, Santosh Kumar, Benjamin G. Steinberg, Yitzhak Reizel, Pinchas Polonsky, Igor E. Koman, Vadim Levitt, Albert Pinhasov, Andriy Marusyk, , Michael Y. Sherman

The paper shows that cancer cells generate non-random, high-frequency mutations during drug adaptation, enriched near transcription factor binding sites.

bioRxiv · Feb 23, 2026 · PreprintCancer Biology